Cationic liposomes enhance adenovirus entry via a pathway independent of the fiber receptor and alpha(v)-integrins.
The ability of adenoviral vectors to mediate efficient gene delivery both in vitro and in vivo is limited by the availability of specific cell surface receptors and alpha(v)-containing integrins. We tested whether this limitation could be overcome by enhancing viral entry with cationic liposomes. In cultured vascular smooth muscle cells, delivery of adenoviral vectors in the presence of cationic liposomes increased vector-encoded transgene expression up to 20-fold. The increase in transgene expression was associated with the formation of adenovirus-lipid aggregates and an increase in the amount of vector DNA in the cells, suggesting that enhanced viral entry was responsible for the increase in gene expression. Treatment of the cells with an RGD-containing peptide or adenovirus type 5 fiber protein did not diminish liposome enhancement of transgene expression, indicating that liposomes increase viral entry via a pathway independent of the fiber receptor and of alpha(v) integrin-assisted endocytosis. Liposomes also significantly enhanced transgene expression from adenoviral vectors delivered to cells deficient in alpha(v)-containing integrins. The magnitude of liposome enhancement of transgene expression in cultured smooth muscle cells was greatest during brief periods of virus-cell contact and at low concentrations of virus. Despite these promising in vitro results, addition of liposomes did not improve in vivo adenoviral gene delivery into injured rat carotid arteries. Liposomes can improve adenoviral gene delivery in vitro; however, application of this observation to accomplish improved in vivo gene delivery remains a challenge.
Qiu
C
C
Gladstone Institute of Cardiovascular Disease, Department of Medicine, University of California, San Francisco 94141-9100, USA.
De Young
M B
MB
Finn
A
A
Dichek
D A
DA
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D015703:Antigens, CD / Q000502:physiology; D019556:COS Cells; D002213:Capsid / Q000494:pharmacology; D036022:Capsid Proteins; D002339:Carotid Arteries; D002412:Cations; D002478:Cells, Cultured; D003571:Cytochalasin B / Q000494:pharmacology; D004274:DNA, Recombinant / Q000032:analysis; D004279:DNA, Viral / Q000032:analysis; D004337:Drug Carriers; D015870:Gene Expression / Q000187:drug effects; D018014:Gene Transfer Techniques; D005822:Genetic Vectors / Q000235:genetics* / Q000648:ultrastructure; D039564:Integrin alphaV; D008081:Liposomes; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000737:chemistry / Q000166:cytology / Q000821:virology; D009842:Oligopeptides / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011991:Receptors, Virus / Q000502:physiology; D019076:Transgenes / Q000235:genetics; D014771:Virion / Q000648:ultrastructure
D015703:Antigens, CD; D036022:Capsid Proteins; D002412:Cations; D004274:DNA, Recombinant; D004279:DNA, Viral; D004337:Drug Carriers; D039564:Integrin alphaV; D008081:Liposomes; D009842:Oligopeptides; D011991:Receptors, Virus; C085301:adenovirus receptor; C018315:hexon capsid protein, Adenovirus; D003571:Cytochalasin B; C047981:arginyl-glycyl-aspartic acid